- What is SPRY's revenue?
- ARS Pharmaceuticals, Inc. (SPRY)'s most recent annual revenue is $84.3 million for fiscal year 2025 (ended December 31, 2025). The full 10+ year revenue history and quarterly trend are in the Revenue card on this page; analyst forecasts for the next 1–2 fiscal years are in the forward-revenue card below.
- How is SPRY's revenue growing?
- ARS Pharmaceuticals, Inc.'s most recent year-over-year revenue growth was -5.5%. The Revenue card on this page shows the full history with a 5-year CAGR for context; the quarterly view reveals recent acceleration or deceleration.
- What is SPRY's gross margin?
- ARS Pharmaceuticals, Inc. (SPRY)'s most recent annual gross margin is 75.8%. The Margins cascade chart on this page layers gross / operating / net margins together with year-over-year direction — one of the strongest signals for the underlying unit economics.
- What is SPRY's net income?
- ARS Pharmaceuticals, Inc.'s most recent annual net income — total earnings after all expenses, interest, and taxes — was $-171.3 million for fiscal year 2025 (ended December 31, 2025). Annual + quarterly views, growth rate, GAAP vs non-GAAP, and per-share figures are all in the Net Income card on this page.
- How current is SPRY's income statement data?
- The income-statement figures for ARS Pharmaceuticals, Inc. (SPRY) on this page are as of fiscal year 2025 (ended December 31, 2025). New 10-Q (quarterly) and 10-K (annual) filings are typically parsed and reflected here within 48 hours of SEC submission.
